Early trial shows injectable agent illuminates cancer during surgery

Doctors at the Duke University School of Medicine have tested a new injectable agent that causes cancer cells in a tumour to fluoresce, potentially increasing a surgeon’s ability to locate and remove all of a cancerous tumour on the first attempt. Brian Brigman, chief of orthopedic oncology at Duke, said: “Knowing where there is residual disease can also guide radiation therapy, or even reduce how much radiation a patient will receive.”

Medical Xpress